Logotipo del SMU


Uruguayan Medical Journal

ISSN: 1688-0390

Vol.21 - Nº 1 - Mar. 2005

Previous Art | Index | Next Art

Anticoagulants in patients with central nervous system tumors

Rev Med Urug 2005; 21: 23-29
Full text (spanish) |  Full text (spanish) (New windows, pdf) | Abstract


Background: thromboembolic complications are seen in 15% of patients with cancer. Patients with primary or secundary tumors of the central nervous system add to usual risk factors for oncologic patients, specific factors for thromboembolic complications.

Since associated-risk to anticoagulant administration in patients with central nervous system injuries is usually overvalued, it is not usually recommended as prophylactic criteria. On the other way, once tromboembolic complications are proved, a therapeutic dosage must be indicated.

Objective: to assess risk/benefit of anticoagulant administration to patients with central nervous system tumors according to prophylactic and therapeutic criteria.

Methods: a ten-years old specific bibliography was reviewed.

Conclusions: low dosage of anticoagulant administration with warfarine based on risk-benefit assessment and paramedical follow up is indicated in ambulatory patients with encephalic tumors.

Thromboembolic prophylaxis benefit in surgery with low molecular weight heparine overtake haemorragic risk better than neurosurgery.

Patients with thromboembolic complications benefited from anticoagulant administration as far as dosage follow up ranged therapeutic average.